FIELD: chemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a rodent for expression of a modified gene C3, the genome of which comprises replacement of a sequence of a rodent gene C3 in an endogenous locus C3 of a rodent by a sequence of a human C3 gene to form a modified gene C3, as well as a method for production thereof, an embryo and a cell thereof. Also disclosed is rodent for expression of modified gene C3 and modified gene C5. Above rodent genome comprises replacement of the C5 rodent gene sequence by a human C5 gene sequence to form a modified C5 gene and replacing the rodent gene C3 sequence in the rodent endogenous locus C3 by the human C3 gene sequence to form a modified C3 gene. Invention also relates to a method for identifying a compound capable of modulating activation of a complement system involving use of said rodent.
EFFECT: invention enables efficient identification of a compound capable of modulating activation of a complement system.
26 cl, 12 dwg, 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO | 2015 |
|
RU2799086C2 |
HUMANIZED IL-7 RODENTS | 2013 |
|
RU2654565C2 |
ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2703139C2 |
MICE WITH HUMANIZED LIGHT CHAIN | 2012 |
|
RU2761639C2 |
ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2788523C2 |
HUMANIZED M-CSF MICE | 2020 |
|
RU2819731C2 |
HUMANISED M-CSF MICE | 2012 |
|
RU2730643C2 |
NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE | 2014 |
|
RU2670016C1 |
HUMANISED IL-15 ANIMALS | 2014 |
|
RU2674910C2 |
Authors
Dates
2020-02-04—Published
2015-05-04—Filed